The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its legacy within the broader market now presents questions about potential returns . Generic versions are undercutting market share, leading to worries that betting on companies heavily reliant to Viagra's previous position could be a speculative